Literature DB >> 19497975

Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice.

Yingjie Wu1, Hui Sun, Shoshana Yakar, Derek LeRoith.   

Abstract

IGF-I plays a vital role in growth and development and acts in an endocrine and an autocrine/paracrine fashion. The purpose of the current study was to clarify whether elevated levels of IGF-I in serum can rescue the severe growth retardation and organ development and function of igf-I null mice. To address that, we overexpressed a rat igf-I transgene specifically in the liver of igf-I null mice. We found that in the total absence of tissue IGF-I, elevated levels of IGF-I in serum can support normal body size at puberty and after puberty but are insufficient to fully support the female reproductive system (evident by irregular estrous cycle, impaired development of ovarian corpus luteum, reduced number of uterine glands and endometrial hypoplasia, all leading to decreased number of pregnancies and litter size). We conclude that most autocrine/paracrine actions of IGF-I that determine organ growth and function can be compensated by elevated levels of endocrine IGF-I. However, in mice, full compensatory responses are evident later in development, suggesting that autocrine/paracrine IGF-I is critical for neonatal development. Furthermore, we show that tissue IGF-I is necessary for the development of the female reproductive system and cannot be compensated by elevated levels of serum IGF-I.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497975      PMCID: PMC2819739          DOI: 10.1210/en.2009-0272

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  48 in total

Review 1.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

Authors:  R C Baxter
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-06       Impact factor: 4.310

2.  Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system.

Authors:  I Ueki; G T Ooi; M L Tremblay; K R Hurst; L A Bach; Y R Boisclair
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Determining the stage of the estrous cycle in the mouse by the appearance of the vagina.

Authors:  A K Champlin; D L Dorr; A H Gates
Journal:  Biol Reprod       Date:  1973-05       Impact factor: 4.285

4.  Granulosa cell proliferation is impaired in the Igf1 null ovary.

Authors:  R Kadakia; J A Arraztoa; C Bondy; J Zhou
Journal:  Growth Horm IGF Res       Date:  2001-08       Impact factor: 2.372

5.  Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.

Authors:  P F Backeljauw; L E Underwood
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

6.  Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth.

Authors:  F Lupu; J D Terwilliger; K Lee; G V Segre; A Efstratiadis
Journal:  Dev Biol       Date:  2001-01-01       Impact factor: 3.582

Review 7.  Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system.

Authors:  J L Liu; S Yakar; D LeRoith
Journal:  Proc Soc Exp Biol Med       Date:  2000-04

8.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

Review 10.  Genetic characterization of growth hormone deficiency and resistance: implications for treatment with recombinant growth hormone.

Authors:  Gerhard Baumann
Journal:  Am J Pharmacogenomics       Date:  2002
View more
  39 in total

1.  Elevated circulating IGF-I promotes mammary gland development and proliferation.

Authors:  Dara Cannata; Danielle Lann; Yingjie Wu; Sebastien Elis; Hui Sun; Shoshana Yakar; Deborah A Lazzarino; Teresa L Wood; Derek Leroith
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  Hypothalamic insulin-like growth factor-I receptors are necessary for hormone-dependent luteinizing hormone surges: implications for female reproductive aging.

Authors:  Brigitte J Todd; Zaher O Merhi; Jun Shu; Anne M Etgen; Genevieve S Neal-Perry
Journal:  Endocrinology       Date:  2010-01-22       Impact factor: 4.736

Review 3.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 4.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

5.  Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model.

Authors:  Christopher J Romero; Yewade Ng; Raul M Luque; Rhonda D Kineman; Linda Koch; Jens C Bruning; Sally Radovick
Journal:  Mol Endocrinol       Date:  2010-03-08

6.  Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression.

Authors:  Sebastien Elis; YingJie Wu; Hayden-William Courtland; Hui Sun; Clifford J Rosen; Martin L Adamo; Shoshana Yakar
Journal:  Aging Cell       Date:  2011-03-22       Impact factor: 9.304

7.  Hepatic JAK2 protects against atherosclerosis through circulating IGF-1.

Authors:  Tharini Sivasubramaniyam; Stephanie A Schroer; Angela Li; Cynthia T Luk; Sally Yu Shi; Rickvinder Besla; David W Dodington; Adam H Metherel; Alex P Kitson; Jara J Brunt; Joshua Lopes; Kay-Uwe Wagner; Richard P Bazinet; Michelle P Bendeck; Clinton S Robbins; Minna Woo
Journal:  JCI Insight       Date:  2017-07-20

8.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

9.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

10.  Deletion of growth hormone receptors in postnatal skeletal muscle of male mice does not alter muscle mass and response to pathological injury.

Authors:  Archana Vijayakumar; Nicholas J Buffin; Emily J Gallagher; Jeffrey Blank; Yingjie Wu; Shoshana Yakar; Derek LeRoith
Journal:  Endocrinology       Date:  2013-07-16       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.